![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M O'Donnell, RJ Garippa, N Rinaldi, WM Selig, B Simko, L Renzetti, SA Tannu, MA Wasserman, A Welton and DR Bolin
Department of Bronchopulmonary Research, Hoffmann-La Roche, Inc., Nutley, New Jersey.
Ro 25-1553, a cyclic peptide analog of vasoactive intestinal peptide (VIP), was designed to overcome many of the deficiencies inherent in this natural neuropeptide. On isolated guinea pig tracheal smooth muscle, Ro 25-1553 produces concentration-dependent relaxation of contractile responses to a number of different spasmogens. Depending on the contractile stimulus, Ro 25-1553 is 24 to 89 times more potent than VIP as a relaxant of guinea pig trachea. The high potency of Ro 25-1553 extends to studies on isolated, histamine-contracted, human bronchial smooth muscle, where Ro 25-1553 exhibits a 390-fold enhancement over native VIP and is more potent than other bronchodilating drugs, such as the beta 2-adrenoceptor agonists isoproterenol and salbutamol. Ro 25- 1553 was shown to displace the radioligand 125I-VIP from rat forebrain membranes with an IC50 value of 4.98 nM, thereby demonstrating that it acts at a VIP receptor. In addition, when tested in a battery of 40 other binding assays (e.g., muscarinic, histamine, LTs, Ca++, TxA2, endothelin, alpha and beta adrenergic, platelet-activating factor, neurokinins, etc.) at concentrations as high as 10 microM, Ro 25-1553 was found to be inactive; thus it appears to be specific for VIP receptors. The potent smooth muscle relaxant activity exhibited in vitro by Ro 25-1553 is also evident after in vivo intratracheal administration or aerosolization of the compound. Pulmonary responses evoked by histamine, leukotriene D4, platelet-activating factor and acetylcholine are inhibited dose-dependently by intratracheally instilled Ro 25-1553 with nearly identical potency (ED50 values ranging from 0.07 micrograms to 0.26 micrograms).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  H. Igarashi, T. Ito, S. A. Mantey, T. K. Pradhan, W. Hou, D. H. Coy, and R. T. Jensen Development of Simplified Vasoactive Intestinal Peptide Analogs with Receptor Selectivity and Stability for Human Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-Activating Polypeptide Receptors J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 370 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Hinkle, E. Donnelly, D. B. Cody, R. J. Sheldon, and R. J. Isfort Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force J Appl Physiol, February 1, 2005; 98(2): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Akesson, B. Ahren, G. Edgren, and E. Degerman VPAC2-R Mediates the Lipolytic Effects of Pituitary Adenylate Cyclase-Activating Polypeptide/Vasoactive Intestinal Polypeptide in Primary Rat Adipocytes Endocrinology, February 1, 2005; 146(2): 744 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Linden, L Hansson, A Andersson, M Palmqvist, P Arvidsson, C-G Lofdahl, P Larsson, and J Lotvall Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma Thorax, March 1, 2003; 58(3): 217 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Igarashi, T. Ito, T. K. Pradhan, S. A. Mantey, W. Hou, D. H. Coy, and R. T. Jensen Elucidation of the Vasoactive Intestinal Peptide Pharmacophore for VPAC2 Receptors in Human and Rat and Comparison to the Pharmacophore for VPAC1 Receptors J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 445 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Igarashi, T. Ito, W. Hou, S. A. Mantey, T. K. Pradhan, C. D. Ulrich II, S. J. Hocart, D. H. Coy, and R. T. Jensen Elucidation of Vasoactive Intestinal Peptide Pharmacophore for VPAC1 Receptors in Human, Rat, and Guinea Pig J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 37 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ito, W. Hou, T. Katsuno, H. Igarashi, T. K. Pradhan, S. A. Mantey, D. H. Coy, and R. T. Jensen Rat and guinea pig pancreatic acini possess both VIP1 and VIP2 receptors, which mediate enzyme secretion Am J Physiol Gastrointest Liver Physiol, January 1, 2000; 278(1): G64 - G74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gressens, L. Besse, P. Robberecht, I. Gozes, M. Fridkin, and P. Evrard Neuroprotection of the Developing Brain by Systemic Administration of Vasoactive Intestinal Peptide Derivatives J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1207 - 1213. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Harmar, A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, et al. International Union of Pharmacology. XVIII. Nomenclature of Receptors for Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Pharmacol. Rev., June 1, 1998; 50(2): 265 - 270. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
